Joseph Boll

Joseph Boll

Associate Professor - Biological Sciences

We are focused on understanding mechanisms that contribute to antibiotic treatment failure and developing alternative strategies to combat "superbugs".

 
9728836529
FO 3.401
Boll group website
ORCID
Tags: Biochemistry and Chemical Biology Molecular Biology Infectious Disease Biology Pathobiology Microscopy & Cell Imaging Antibiotic Resistance microbiology

Professional Preparation

Postdoctoral - Microbiology/Synthetic Biology
University of Texas at Austin - 2017
PhD - Molecular Biosciences (Microbiology)
University of Texas Southwestern Medical Center - 2013
BSc - Microbiology
Texas Tech University - 2007

Research Areas

Understanding how Gram-negative bacteria survive without lipopolysaccharide
This research topic focused on how Acinetobacter baumannii, which is a nosocomial pathogen, inactivates lipooligosaccharide (LOS) production to develop resistance to colistin, which is the last-line treatment against multidrug resistant Gram-negative bacteria. Using high-throughput sequencing, lipidomics, and mass spectrometry we found that the outer membrane is remodeled when LOS is not made. Specifically, a compensatory mutation of the class A penicillin-binding protein, PBP1A is required for A. baumannii survival without lipid A. My research group is currently working to elucidate the cell wall modifications that support Gram-negative survival without lipid A.

Characterizing chemical modifications that promote antimicrobial resistance in nosocomial Gram-negative pathogens:
Bacteria remodel their surface with chemical moieties to fortify the barrier and protect the cell from toxins, such as antimicrobials. We recently found that some Gram-negative "superbigs" modify the lipid A portion of lipopolysaccharide with aminoarabinose to induce cationic antimicrobial peptide heteroresistance and beta-lactam tolerance. The chemical modification is regulated by the PhoPQ two-component system. Furthermore, we have characterized various modifications that lead to antimicrobial resistant in other Gram-negative bacteria.

Publications

PBP1A directly interacts with the divisome complex to promote septal peptidoglycan synthesis in Acinetobacter baumannii 2022 - Other
Peptidoglycan Recycling Promotes Outer Membrane Integrity and Carbapenem Tolerance in Acinetobacter baumannii. 2022 - Journal Article
In Mycobacterium abscessus , the Stringent Factor Rel Regulates Metabolism but Is Not the Only (p)ppGpp Synthase 2022 - Journal Article
High-level carbapenem tolerance requires antibiotic-induced outer membrane modifications. 2022 - Journal Article
PBP1A Directly Interacts with the Divisome Complex to Promote Septal Peptidoglycan Synthesis in Acinetobacter baumannii 2022 - Journal Article
A nematode-derived, mitochondrial stress signaling-regulated peptide exhibits broad antibacterial activity. 2021 - Journal Article
Septal Class A Penicillin-Binding Protein Activity and ld -Transpeptidases Mediate Selection of Colistin-Resistant Lipooligosaccharide-Deficient Acinetobacter baumannii 2021 - Journal Article
High-level carbapenem tolerance requires antibiotic-induced outer membrane modifications 2021 - Other

Presentations

Molecular interactions between peptidoglycan maintenance and outer membrane lipid asymmetry in Acinetobacter baumannii.
2023/06 13th International Symposium on the Biology of Acinetobacter
A molecular basis for antibiotic treatment failure in carbapenem susceptible Gram-negative bacteria
2023/06 Houston Methodist Research Institute  - Gulf Coast Consortia
Molecular factors that promote antibiotic treatment failure in Gram-negative infections
2023/04 UT Health Houston
The molecular basis for antibiotic treatment failure
2023/03 Texas Women’s University

Affiliations

mBio
Junior Editorial Board Member

Funding

Reinforcing the barrier: Understanding how cell envelope modifications promote intrinsic antimicrobial tolerance and resistance in Acinetobacter baumannii
- NIH/NIGMS [2021/07–2026/04]
R35GM143053
Mechanistic basis of how LD-transpeptidases protect against outer membrane defects
- NIH/NIAID [2022/03–2027/02]
R01AI168159
Solving a Multidrug Resistance Puzzle: Complete Loss of Lipooligosaccharide
- NIH/NIAID [2019/06–2021/05]
R21AI146829